Effect of Topical Anesthesia on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery.

Coronary Artery Disease Clinical Trial

Official title:

Effect of Topical Anesthesia Combined With Intravenous Induction on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery: a Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04744480
• Other study ID #: TACTICS
• Status: Completed
• Phase: N/A
• Start date: March 5, 2021
• Est. completion date: April 27, 2022

Study information

• Verified date: May 2022
• Source: Qianfoshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the induction is to decrease stress response of endotracheal intubation. It is also important to keep hemodynamics stable during and after the induction period. Previous studies have shown that topical anesthesia can provide excellent superior supraglottic and subglottic local anesthetic effects and can significantly reduce the dosage of intravenous anesthetics. Therefore, it is significant to explore whether the combination of topical anesthesia and intravenous anesthetics could decrease the stress response of endotracheal intubation and keep hemodynamics stable during and after the induction period.

Description:

The routine anesthesia induction strategy for cardiac surgery is to decrease stress response during endotracheal intubation by using large doses of opioids. However, high doses of opioids often leads to persistent and recurrent hypotension in patients from the anesthesia induction period to the beginning of the surgery. Patients scheduled to accept cardiac surgery often have severe concomitant disease. Hemodynamic fluctuation might lead to disastrous events. Anesthesia induction for such patients should not only provide adequate depth of anesthesia to decrease the stress response of endotracheal intubation, but also make hemodynamics stable after tracheal intubation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: April 27, 2022
• Est. primary completion date: April 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patients scheduled to accept elective /major cardiac surgery;

2. Patients older than 18 years and younger than 85 years;

3. Patients of The American Society of Anesthesiologists ( ASA )? - ? level grade;

4. Patients signed the informed consent form for the clinical study;

Exclusion Criteria:

1. Patients cannot cooperate to topical anesthesia;

2. Patients with a left cardiac assist device prior to surgery;

3. Patients with aortic dissection;

4. Patients with Intra Aortic Balloon Pump (IABP) prior to surgery;

5. Patients treated with Extracorporeal Membrane Oxygenation (ECMO) prior to surgery;

6. Patients with difficult airway;

7. Patients with high sensitivity and hypersensitivity to lidocaine and tetracaine;

8. Patients with atrioventricular block;

9. Hemoglobin(Hb)<80g/L;

10. Patients who have participated in other clinical studies during the last 3 months;

Related Conditions & MeSH terms

• Arrhythmia
• Cardiomyopathies
• Coronary Artery Disease
• Heart Diseases
• Heart Valve Diseases
• Myocardial Disease
• Valvular Heart Disease

Intervention

Procedure:
• The combined topical anesthesia induction group
The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia,3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.

Locations

Country	Name	City	State
China	Meng-Lv	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qianfoshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the curve of baseline blood pressure	The area under the curve (AUC) of blood pressure below baseline from the beginning of general anesthesia induction to the surgery beginning.	From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.
Secondary	The frequency and types of vasoactive drugs used.	The frequency and types of vasoactive drugs used ,such as the use of norepinephrine and dopamine.	From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.
Secondary	The incidence of arrhythmias.	The incidence of arrhythmias, such as atrioventricular block, atrial fibrillation, ventricular tachycardia and so on.	From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.
Secondary	cardiac systolic function:Left Ventricular Ejection Fraction (LVEF)	Left ventricular ejection fraction is a reliable indicator of left ventricular systolic function. left ventricular ejection fraction (LVEF) (?)= stroke output (SV)/ left ventricular end-diastolic volume (LEDV)×100?	Preoperative, intraoperative
Secondary	cardiac diastolic function:E/E' (the ratio of E peak and E') or E/A :(the ratio of E peak and A peak)	E/A ratio, one of the main indicators for evaluating diastolic function, indicated normal diastolic function when E/A >1, and decreased diastolic function when E/A < 1.	Preoperative, intraoperative
Secondary	cardiac output monitoring indicator: CO(cardiac output)	CO=Stroke Output (SV)× Heart Rate (HR).The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.	Intraoperative
Secondary	cardiac output monitoring indicator: SVV(stroke volume variation)	The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.	Intraoperative
Secondary	cardiac output monitoring indicator: CI(cardiac index)	CI=CO/ Body Surface Area (BSA).The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.	Intraoperative
Secondary	cardiac output monitoring indicator: SVR (systemic vascular resistance)	SVR=60×(MAP-CVP)/CO. MAP: mean arterial pressure. CVP: central venous pressure.The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.	Intraoperative
Secondary	The number of patients with postoperative hoarseness.	Hoarseness was classified as mild, moderate and severe according to the severity.	Three days after the surgery
Secondary	The number of patients with postoperative sore throat.	Sore throats can be evaluated using the Numeric Pain Scale (NRS) pain numerical score.	Three days after the surgery